At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACTU Actuate Therapeutics Inc
Market Closed 04-17 16:00:00 EDT
8.00
-0.23
-2.79%
盘后8.00
+0.000.00%
16:00 EDT
| High8.23 | Low7.92 | Vol51.96K |
| Open8.07 | D1 Closing8.23 | Amplitude3.77% |
| Mkt Cap156.25M | Tradable Cap47.70M | Total Shares19.53M |
| T/O417.69K | T/O Rate0.87% | Tradable Shares5.96M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
GlobeNewswire · 04-17
ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission
Sydney Morning Herald · 04-03
ACTU pushes for 4.5 per cent lift in minimum wage at Fair Work Commission
BRIEF-Actuate Therapeutics Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc
Reuters · 03-28
BRIEF-Actuate Therapeutics Files Prospectus To Offer, Sale Of Up To 3.9 Million Shares By B. Riley Principal Capital II, LLC
Reuters · 03-28
Actuate Therapeutics Files Prospectus to Offer, Sale of up to 3.9 Mln Shares by B. Riley Principal Capital Ii, Llc -SEC Filing
THOMSON REUTERS · 03-28
Actuate Therapeutics Inc - Have the Right to Sell up to $50 Million Newly Issued Shares - SEC Filing
THOMSON REUTERS · 03-28
Actuate Therapeutics Inc - Enters Stock Purchase Agreement With B. Riley Principal Capital Ii, Llc - SEC Filing
THOMSON REUTERS · 03-28
‘Completely unrealistic’: Four-day Aussie work week seemingly a long way off
Sydney Morning Herald · 03-19
‘Completely unrealistic’: Four-day Aussie work week seemingly a long way off
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital
Reuters · 03-17
BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, Incyte
Reuters · 03-17
BUZZ-H.C. Wainwright starts coverage on Actuate Therapeutics with 'buy' rating
Reuters · 03-17
Actuate Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 03-17
Actuate Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $20
THOMSON REUTERS · 03-17
ACTU targets blue-collar seats to protect Labor, defend IR gains
The Australian Financial Review · 03-02
Actuate Therapeutics completes enrollment in Phase 2 trial of elraglusib
TIPRANKS · 02-25
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination With Folfirinox and Losartan in Patients With Previously Untreated Metastatic Pancreatic Cancer
THOMSON REUTERS · 02-25
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
GlobeNewswire · 02-25
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
Simply Wall St. · 02-12
Assault on retail penalty rates may spread to other jobs: ACTU
The Australian Financial Review · 01-28
ACTU: Aussies could be $165K worse off under a push to change superannuation guarantee
Sydney Morning Herald · 01-17
ACTU: Aussies could be $165K worse off under a push to change superannuation guarantee
Introduction
Company Name.
Actuate Therapeutics Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App